Research and Markets has announced the addition of the "Global Hepatitis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2020" report to their offering.
The global hepatitis drugs market accounted for revenue of $23,222.1 million in 2014, and it is expected to grow with a CAGR of 29.7% during 2015 - 2020. Among the various types, the hepatitis C segment dominated the global hepatitis drugs market, with 76.1% share in 2014.
The global market of hepatitis drugs is up surging with a significant rate, due to increasing incidences of hepatitis, and increasing support from government organizations. Hepatitis is one of the leading causes of death around the world. According to the Hepatitis B Foundation, every year around 1 million deaths are recorded due to hepatitis B and its complications around the world. In the case of hepatitis C, the WHO stated that approximately 500,000 deaths are reported globally every year from hepatitis C related infections.
The increasing participation of various government organizations is leading to increasing awareness about various types of hepatitis infections and their management. Several government organizations are providing support, in form of funding and initiatives implemented by them for enhancing prevention, offering drug therapies, encouraging testing, and providing patient-centric services.
The key companies operating in the global hepatitis drugs market include Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline PLC, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, and Mitsubishi Tanabe Pharma Corporation.
Key Topics Covered:
1. Research Scope & Methodology
4.Global Hepatitis Drugs Market Size And Forecast (2011-2020)
5.Global Hepatitis Drugs Market Breakdown By Type
6.Global Hepatitis Drugs Market Breakdown By Geography
7.Pipeline Drugs For Hepatitis
8.Drug Approval Process In The .S. And Eu
9.Competitive Positioning And Market Share Analysis
10.Company Profiles And Strategic Developments
For more information about this report visit http://www.researchandmarkets.com/research/p3rmxl/global_hepatitis